Placebo Control

[Originally posted on First Patient In ] In my experience, most clinical trials do not suffer from significant retention issues. This is ...

It is a surprisingly common peril among analysts: we don’t have the data to answer the question we’re interested in, so we answer a related ...

Near the end of last year, I had the bright idea of starting a second blog, Placebo Lead-In , to capture a lot of smaller items that I foun...

Are we looking at our enrollment data in the right way? I will be chairing a session on Tuesday on this topic, joined by a couple of g...

Are competing trials slowing yours down? Probably not. If they don't like your trial, EVERYTHING ELSE IN THE WORLD is competition fo...

Can you shed three years of pipeline flab with this one simple trick? "There’s no trick to it ... it’s just a simple trick!"  -...

The many flavors of wish-based patient recruitment. [Hopefully-obvious disclosure: I work in the field of clinical trial enrollment .] ...

'Competitive enrollment' is exactly that. This is a graph I tend to show frequently to my clients – it shows the relative enrollm...

ENACCT has released its final report on the outcomes from the National Cancer Clinical Trials Pilot Breakthrough Collaborative (NCCTBC) , a...

It’s Gresham’s Law for clinical trial metrics: Bad data drives out good. Here are 4 steps you can take to fix it. Many years ago, when I ...

Will physicians change their answers when tired of alerts? I am an enormous fan of electronic health records (EMRs).  Or rather, more pre...

* for some value of "most" ** for some value of "too" [Note: this is a companion to a previous post, Clouding the Deba...

I would like to propose a rule for clinical trial benchmarks. This rule may appear so blindingly obvious that I run the risk of seeming simp...

I know it’s not even August yet, but I think we can close the nominations for "Worst Trial Metric of the Year".  The hands-down wi...